伊梅格林对2型糖尿病患者线粒体功能的影响:一项前性队列研究
Abhishek Satheesan1, Janardanan Kumar2, Kakithakara Vajravelu Leela1
1Department of Microbiology, SRM Medical College Hospital and Research Centre, SRM Institute of Science and Technology (SRMIST), Kattankulathur, Chengalpattu, Tamil Nadu, India.
Frontiers in endocrinology
|August 18, 2025
概括
伊梅格林的联合治疗显著改善了2型糖尿病 (T2DM) 患者的血糖控制和线粒体功能. 单一疗法显示出有限的益处,这表明组合疗法是代谢健康的首选方法.
科学领域:
- 内分泌学和新陈代谢学
- 线粒体生物学 线粒体生物学
- 遗传学 是一个遗传学.
背景情况:
- 2型糖尿病 (T2DM) 是一种代谢障碍,其特征是葡萄糖调节受损.
- 伊梅格林是一种新的口服降糖剂,向线粒体功能.
- 这项研究调查了Imeglimin对T2DM的血糖控制,线粒体DNA (mtDNA) 拷贝数和端粒动态的影响.
研究的目的:
- 评估Imeglimin单独和组合的疗效,对T2DM患者的血糖控制.
- 评估基于Imeglimin的疗法对线粒体DNA (mtDNA) 拷贝数的影响.
- 在T2DM治疗的背景下,研究Imeglimin对端粒动态的影响.
主要方法:
- 一项涉及T2DM患者的临床试验分为四组:伊梅格林单一治疗,伊梅格林+甲福林,伊梅格林+其他口服低血糖剂 (OHA),以及梅格林+其他OHA.
- 评估临床和代谢参数,包括HbA1c,mtDNA拷贝数和基线和六个月的相对端粒长度.
- 使用配对t测试和混合模型来确定治疗效果的统计分析.
主要成果:
- 在所有治疗组中都观察到显著的HbA1c降低,Imeglimin组合显示出明显的效果.
- 基于伊梅格林的组合疗法导致mtDNA拷贝数显著增加,表明线粒体功能得到改善.
- 没有观察到相对端粒长度的显著变化,只与年龄和LDL-c水平相关.
结论:
- 基于伊梅格林的组合疗法在改善血糖控制和增强T2DM中的线粒体功能方面表现出显著的疗效.
- 与组合策略相比,伊梅格林单一治疗提供了有限的代谢益处.
- 与Imeglimin的联合治疗可能是优化T2DM患者代谢结果的首选方法.
相关概念视频
Diabetes Mellitus: Type 2 and Gestational
2.9K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.9K
Oral Hypoglycemic Agents: Biguanides and Glitazones
291
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
291
Dipeptidyl Peptidase 4 Inhibitors
256
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
256
Diabetes Mellitus: Overview and Type I Subtype
3.2K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
3.2K
Carbohydrate Metabolism
11.7K
Carbohydrates are polymers composed of molecules containing atoms of carbon, hydrogen and oxygen. One gram of carbohydrate can provide four kilo-calories of energy, which makes it the most efficient instant energy source.
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...
11.7K
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
256
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
256


